Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, ...

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.

Opens in a new tab or window "While we await results from ongoing prospective trials, our data suggest that treatment decisions should consider both the prior history of CDK4/6i benefit and the ...

Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer. At the 42nd Annual Miami Breast Cancer Conference, Dr. Sara M. Tolaney sat down for ...

Gene expression testing helps determine chemotherapy needs for HR+ breast cancer, optimizing treatment and reducing ...

While the global CDK4/6 inhibitor market remains highly competitive, VERZENIO's distinct clinical advantages and ongoing studies could contribute to further market expansion. VERZENIO (abemaciclib ...

Using an unbiased approach, this important study discovered a role of Ezh2 in the differentiation of granule neuron precursors, the cell of origin for Shh group of medulloblastoma. Furthermore, the ...